National Authority for Health: France
- PMID: 19639712
National Authority for Health: France
Abstract
The French National Authority for Health (Haute Autorité de Santé, or HAS) was established to assist France's public institutions in optimizing the basket of reimbursable goods and services and to help health care professionals continuously improve their clinical practice by defining best-care standards and identifying relevant tools and methods. HAS carries out single technology assessment (STA) and multiple technology assessment (MTA), assessing both the intrinsic benefit of the new technology and its effectiveness compared with that of existing technologies. A new treatment may not be covered unless it provides either improved benefit or lower cost, and STA is mandatory before a new drug, device, or medical procedure can be added to the benefit list for sickness funds. While HAS recommendations are advisory, the decision-making bodies (the Ministry of Health or the union of sickness funds) accept its findings in most cases.
Similar articles
-
Evidence-based decision-making within Australia's pharmaceutical benefits scheme.Issue Brief (Commonw Fund). 2009 Jul;60:1-13. Issue Brief (Commonw Fund). 2009. PMID: 19639714
-
Institute for Quality and Efficiency in Health Care: Germany.Issue Brief (Commonw Fund). 2009 Jul;57:1-12. Issue Brief (Commonw Fund). 2009. PMID: 19639711
-
How should cost-effectiveness analysis be used in health technology coverage decisions? Evidence from the National Institute for Health and Clinical Excellence approach.J Health Serv Res Policy. 2007 Apr;12(2):73-9. doi: 10.1258/135581907780279521. J Health Serv Res Policy. 2007. PMID: 17407655
-
Decision making the explicit evidence-based way: comparing benefits, harms and costs.Nurs Prax N Z. 1999 Mar;14(1):33-42. Nurs Prax N Z. 1999. PMID: 10481662 Review.
-
Health technology assessment and policy decisions on hyperbaric oxygen treatment.Int J Technol Assess Health Care. 1999 Fall;15(4):661-70. Int J Technol Assess Health Care. 1999. PMID: 10645107 Review.
Cited by
-
Funding decisions for newborn screening: a comparative review of 22 decision processes in Europe.Int J Environ Res Public Health. 2014 May 19;11(5):5403-30. doi: 10.3390/ijerph110505403. Int J Environ Res Public Health. 2014. PMID: 24852389 Free PMC article. Review.
-
A systematic review of cost-sharing strategies used within publicly-funded drug plans in member countries of the organisation for economic co-operation and development.PLoS One. 2014 Mar 11;9(3):e90434. doi: 10.1371/journal.pone.0090434. eCollection 2014. PLoS One. 2014. PMID: 24618721 Free PMC article.
-
Health technology funding decision-making processes around the world: the same, yet different.Pharmacoeconomics. 2011 Jun;29(6):475-95. doi: 10.2165/11586420-000000000-00000. Pharmacoeconomics. 2011. PMID: 21568357 Review.
-
Involving patients in reducing decision uncertainties around orphan and ultra-orphan drugs: a rare opportunity?Patient. 2015 Feb;8(1):29-39. doi: 10.1007/s40271-014-0106-8. Patient. 2015. PMID: 25516506
-
Role of centralized review processes for making reimbursement decisions on new health technologies in Europe.Clinicoecon Outcomes Res. 2011;3:117-86. doi: 10.2147/CEOR.S14407. Epub 2011 Aug 30. Clinicoecon Outcomes Res. 2011. PMID: 22046102 Free PMC article.